legislation: 114-s-3269

Congressional bills and resolutions from Congress.gov, filtered to policy areas relevant to environmental, health, agriculture, and wildlife regulation.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

bill_id congress bill_type bill_number title policy_area introduced_date latest_action_date latest_action_text origin_chamber sponsor_name sponsor_state sponsor_party sponsor_bioguide_id cosponsor_count summary_text update_date url
114-s-3269 114 s 3269 Cannabidiol Research Expansion Act Crime and Law Enforcement 2016-07-14 2016-07-14 Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5169) Senate Sen. Feinstein, Dianne [D-CA] CA D F000062 4 Cannabidiol Research Expansion Act This bill requires the Drug Enforcement Administration (DEA) and the Department of Health and Human Services to each evaluate whether cannabidiol, the nonpsychoactive substance derived from marijuana or the synthetic formulation, should be a controlled substance under the Controlled Substances Act. After taking into consideration the evaluations, the DEA must initiate proceedings for classifying cannabidiol as a controlled substance if control is warranted. The bill expands the authority for: (1) conducting medical research on cannabidiol, and (2) possessing or transporting cannabidiol or any other nonpsychoactive component of marijuana for certain medicinal purposes. Physicians who are licensed under state law may discuss the potential harms and benefits of cannabidiol or those components of marijuana as a treatment with their patients or the legal guardians of underage patients. The bill terminates four years after enactment. 2023-01-11T13:33:11Z  

Links from other tables